The US Food and Drug Administration is considering how to provide the public with more details on the use of patient-focused drug development (PFDD) information during drug reviews, while still navigating sponsors’ commercially confidential information protections.
Nicole Verdun, director of the Office of Therapeutic Products, acknowledged during a recent FDA-Duke Margolis Center for Health Policy public meeting on advancing the development of therapeutics through rare disease patient community
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?